The globalization of clinical trials can bring both health benefits and hazards to research subjects and the general population. Potential benefits include diffusion of medical knowledge and ...

Decentralized trials (DCTs) have been linked to increased participation rates of people of underserved populations.

Yet, this lack of bespoke options is more or less the reality of medicine today. Despite the many biological differences between people of different genders, races, ages and life histories, chances ...

The World Health Organization wants to tackle inequity and bureaucracy relating to clinical trials. Will its latest guidance make a difference? Anna Volkmer reports During the covid-19 pandemic the UK ...

Anti-LGBTQI+ public policies overwhelmingly target youth and young adults, disrupting access to educational opportunities, ...

The removal of FDA guidance on clinical trial diversity and related anti–diversity, equity, and inclusion (DEI) actions may hinder progress toward equitable health care, impacting workforce diversity, ...